HAEMATO AG, which is majority-owned by M1 Kliniken AG, has received a so-called Conditional Binding Offer (CBO) for the acquisition of its trading segment, the wholly-owned subsidiary HAEMATO PHARM GmbH. The Executive Board and Supervisory Board of HAEMATO AG are currently carefully reviewing the offer.
A possible sale of the trade segment would pave the way for a clear strategic focus of M1 Kliniken AG on the fast-growing beauty business.
The company will provide further information in due course.
As announced on 20 June 2024, Management Board member Attila Strauss has sold part of his stake in M1 Kliniken AG for personal financial reasons. Mr Strauss continues to hold a tangible stake of over 2.3% in M1 Kliniken AG.
Kilian Brenske, member of the Management Board since 2022, has asked the Supervisory Board to terminate his position on the Management Board for private reasons. The areas of national and international expansion, marketing, purchasing and sales, which he was previously responsible for together with Co-CEO Attila Strauss, will in future be managed by Attila Strauss alone.
In the first quarter of 2024, the M1 Group increased its consolidated sales by 9.6% from EUR 76.8 million to EUR 84.7 million. In comparison, operating earnings before interest and taxes (EBIT) increased at a disproportionately high rate. M1 improved Group EBIT by 70% from EUR 4.0 million to EUR 6.8 million. The Group EBIT margin increased accordingly from 5.3% to 8.1%.
The Supervisory Board of M1 Kliniken AG (ISIN:DE000A0STSQ8) today approved the annual financial statements and the consolidated financial the annual financial statements and the consolidated financial statements of the financial year 2023 presented by the Management Board in accordance with Sections 171, 172 AktG. The annual financial statements are thus adopted in accordance with Section 172 AktG.
The Management Board of M1 Kliniken AG today resolved to repurchase up to 1,000,000 shares of the Company in a maximum total volume of EUR 12,600,000.00 (excluding incidental acquisition costs).
M1 Kliniken AG publishes preliminary figures for financial year 2023:
M1 continues to grow - sales growth of over 10% to € 316,3 million; EBIT increases by 68% to € 15.7 million and the Group's equity increases to € 143.7 million.
By acquiring the German Nutri Care GmbH and its wholly-owned subsidiary, the Dutch online pharmacy "Direct Apotheke Venlo B.V.," M1 Kliniken AG (ISIN: DE000A0STSQ8) taps into a significant growth field and expands the value chain of its health services. Direct Apotheke Venlo B.V., based in Maasbree (NL), is one of the rapidly growing providers in the online pharmacy business for aesthetic pharmaceuticals, with current core markets in Germany and the Netherlands. In the fiscal year 2022, the company recorded double-digit million-euro revenues and continues on a growth trajectory.
We use cookies on our website.Some of them are essential, while others help us to improve this website and your experience.
Technically necessary tools that enable essential services and basic functions, including identity verification, service continuity and site security. This option cannot be denied.
Schützt vor Cross-Site-Request-Forgery Angriffen.
Speichert die aktuelle PHP-Session.
Third-party content, e.g. stock widgets, are blocked by default. If third-party cookies are accepted, access to this content no longer requires manual consent.
We use the TradingView to display stock charts. This provider uses additional cookies to analyze its services.
By using this website, you consent to the use of cookies. You can find detailed information on the use of cookies on this website in the data protection declaration.